Compass Therapeutics Q2: Tovecimig ORR Improves to 18%, FDA Meeting This Month
CMPX sits 20% above its 52-week low of $1.61.
Summary
Compass reported Q2 2026 financials and a pipeline update. The lead asset tovecimig's final ORR improved to 18.0% (p=0.0228) from 17.1%, strengthening the case for a BLA filing. The company plans to engage the FDA later this month, with feedback expected in Q3. The full dataset was selected for an oral presentation at ESMO in October. Cash runway extends into 2028, funding operations through key milestones. CTX-8371 cohort expansions are enrolling in three tumor types, and CTX-10726 has dosed its first patients. These updates follow the positive Phase 2/3 data announced in April and the corporate presentation filed in July. The FDA meeting this month is the next major catalyst.
At the time of this announcement, CMPX was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $340.4M. The 52-week trading range was $1.61 to $6.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.